Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage
- PMID: 31796734
- PMCID: PMC6890647
- DOI: 10.1038/s41467-019-13167-5
Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage
Abstract
The DNA repair capacity of human cells declines with age, in a process that is not clearly understood. Mutation of the nuclear envelope protein barrier-to-autointegration factor 1 (Banf1) has previously been shown to cause a human progeroid disorder, Néstor-Guillermo progeria syndrome (NGPS). The underlying links between Banf1, DNA repair and the ageing process are unknown. Here, we report that Banf1 controls the DNA damage response to oxidative stress via regulation of poly [ADP-ribose] polymerase 1 (PARP1). Specifically, oxidative lesions promote direct binding of Banf1 to PARP1, a critical NAD+-dependent DNA repair protein, leading to inhibition of PARP1 auto-ADP-ribosylation and defective repair of oxidative lesions, in cells with increased Banf1. Consistent with this, cells from patients with NGPS have defective PARP1 activity and impaired repair of oxidative lesions. These data support a model whereby Banf1 is crucial to reset oxidative-stress-induced PARP1 activity. Together, these data offer insight into Banf1-regulated, PARP1-directed repair of oxidative lesions.
Conflict of interest statement
K.J.O. and D.J.R. are founders of CARP Pharmaceuticals. E.B, D.J.R and K.J.O. are founders of Carpe Vitae Pharmaceuticals. E.B., J.T.B, K.J.O. and D.J.R. are inventors on provisional patent applications filed by Queensland University of Technology. D.A.S is a founder, equity owner, advisor, director, consultant, investor and/or inventor on patents licensed to Vium, Jupiter Orphan Therapeutics, Cohbar, Galilei Biosciences, Wellomics, EdenRoc Sciences (affiliates Arc-Bio, Dovetail Genomics, Claret, Revere, UpRNA, MetroBiotech, Liberty) and Life Biosciences (affiliates Selphagy, Senolytic Therapeutics, Spotlight Therapeutics, Immetas, Animal Biosciences, Iduna, Continuum, Jumpstart). He is an inventor on a patent application filed by Harvard Medical School licensed to Elysium Health. See
Figures
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous
